Millions of Americans with diabetes struggle with diabetic peripheral neuropathy, an often painful complication of the disease that usually starts in the feet and legs before moving up to the hands and arms.
Medicare Expands Coverage For Spinal Cord Stimulation To Treat Diabetic Peripheral Neuropathy
Nevro Executives Say Their Device Offers An Option For Patients With Pain
Medicare’s recent expansion of coverage for spinal cord stimulation therapy to treat diabetic peripheral neuropathy could mean relief for some 11 million Americans. Executives from Redwood City, CA device maker Nevro talked to Medtech Insight about the expansion and what it means for patients who use their technology.
More from Diabetic Care
• By
People living with diabetes who receive continuous glucose monitors (CGMs) through medical supply firms show higher compliance, lower costs of care, and fewer hospitalizations after one year than those who use pharmacies, a new study shows.
• By
Even if manufacturing challenges don’t derail the 2025 launch plans, the regulatory setback introduces new challenges for Dexcom’s continuous glucose monitors at a time when competition from Abbott and Medtronic is intensifying.
• By
Abbott’s international sales could be a key driver as firm looks to partnerships with insulin pump companies.
• By
Tempering expectations on the immediate market impact for the upgraded continuous glucose monitor, Dexcom notes insurance coverage and pump integrations will take time to finalize.
More from Device Area
• By
Medtech Insight sat down with Intuitive Surgical CEO Gary Guthart at the recent LSI USA conference to discuss the full launch of the new da Vinci 5 robotic system and planned digital enhancements. Guthart also offered his views on health care interoperability, AI regulation, outpatient surgeries, autonomous robots, and how the company is harnessing technology to shape the future of robotic surgery.
• By
People living with diabetes who receive continuous glucose monitors (CGMs) through medical supply firms show higher compliance, lower costs of care, and fewer hospitalizations after one year than those who use pharmacies, a new study shows.
• By
Cambridge, UK-based breath biopsy company Owlstone Medical will apply its volatile organic compound analysis platform in an attempt to develop a test for the identification and monitoring of pseudomonas aeruginosa in patients with cystic fibrosis.